Sungkyunkwan University · Medicine
Professor Hee Chul Park's research lab specializes in developing innovative nanotherapeutic strategies to overcome treatment resistance in solid tumors, particularly focusing on radiation therapy (RT) enhancement in hypoxic and radioresistant cancers such as pancreatic and hepatocellular carcinoma (HCC). The lab integrates nanomaterials, such as fucoidan-coated manganese dioxide nanoparticles, to alleviate tumor hypoxia and improve RT efficacy. They also investigate the synergistic effects of combining RT with immunotherapies like nivolumab, aiming to optimize treatment sequencing and improve clinical outcomes. Their work bridges preclinical research with translational applications, guiding clinical trial design and practice guidelines in liver cancer.
Figures are computed from collected data and may differ slightly.
Tumor hypoxia is a major mechanism of resistance to radiation therapy (RT), which is associated with poor prognosis in affected cancer patients. Various approaches to treat hypoxic and radioresistant cancers, including pancreatic cancer, have shown limited success. Fucoidan, a polysaccharide from brown seaweed, has antitumor and antiangiogenesis activities. Here, we discuss the development of fucoidan-coated manganese dioxide nanoparticles (Fuco-MnO₂-NPs) and testing of the therapeutic potential
A consensus meeting to develop practice guidelines and to recommend future clinical trials for radiation therapy (RT), including external beam RT (EBRT), and selective internal RT (SIRT) in hepatocellular carcinoma (HCC) was held at the 5th annual meeting of the Asia-Pacific Primary Liver Cancer Expert consortium. Although there is no randomized phase III trial evidence, the efficacy and safety of RT in HCC has been shown by prospective and retrospective studies using modern RT techniques. Based
Previous and/or concurrent application of RT in the course of nivolumab treatment was related with longer PFS and OS in advanced HCC patients. Nonetheless, further clinical studies are warranted to confirm our findings.
Open papers in the app to read, cite, and organize with AI.
